The targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while also improving symptoms for patients with a rare blood disorder called nonadvanced system mastocytosis, according to results of the Phase II SUMMIT trial reported by researchers at The University of Texas MD Anderson Cancer Center.
Senate confirms Monica Bertagnolli to lead NIH with bipartisan 62-36 vote
Monica Bertagnolli passed through the final step to become President Biden’s first Senate-confirmed NIH director in nearly two years with a 62-36 vote on Tuesday.
November 8, 2023